Skip to content
Screener

Precigen PGEN Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
ALN
Alnylam PharmaceuticalsALNY
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$2.51B+388%
Enterprise value$2.6B+414%
P/S94.4×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Precigen’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356090-26-000017

Under the Company’s amended and restated articles of incorporation, the Company is authorized to issue 700,000,000 shares of common stock and 25,000,000 shares of preferred stock.

Item 1. Condensed Consolidated Financial Statements

FAQ

What is Precigen's preferred stock, shares authorized?
Precigen (PGEN) reported preferred stock, shares authorized of $25M in Q1 2026.
How has Precigen's preferred stock, shares authorized changed year-over-year?
Precigen's preferred stock, shares authorized decreased by 0.0% year-over-year, from $25M to $25M.

Ask your AI about Precigen's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude